Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Biotech, RNA Interference, Life Sciences

RXi Obtains License to RNAi Delivery Technology From UMass Medical School

Luke Timmerman 10/14/08

RXi Pharmaceuticals, a Worcester, MA-based developer of drugs based on RNA interference technology, said today it has obtained an exclusive worldwide license to certain technology for oral delivery of RNAi drugs. The technology was developed by Michael Czech and Gary Ostroff at the University of Massachusetts Medical School. Financial terms were not disclosed.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.